Affiliation:
1. Department of Epidemiology, Infectious Disease Control and Prevention Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
2. Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma Hiroshima University Hiroshima Japan
3. Department of Hepatology Research Institute of Virology Tashkent Uzbekistan
4. National Payment Certification Agency Ministry of Economy and Finance Phnom Penh Cambodia
Abstract
AbstractAimThis study investigated hepatitis E virus (HEV) prevalence among pregnant women in Siem Reap, Cambodia, by developing a cost‐effective, user‐friendly in‐house enzyme‐linked immunosorbent assay (ELISA) for detecting total anti‐HEV immunoglobulins (Ig).MethodsThe in‐house ELISA was designed for large‐scale screening in resource‐limited settings. Its performance was benchmarked against two commercial tests: the Anti‐HEV IgG EIA (Institute of Immunology, Co. Ltd) and the Anti‐HEV IgG RecomLine LIA (Mikrogen). The in‐house ELISA demonstrated a sensitivity of 76% and 71.4%, and a specificity of 94.1% and 98.6%, against the two commercial tests, respectively, with overall agreement rates of 92.4% and 94.3%.ResultsAmong 1565 tested pregnant women, 11.6% were anti‐HEV positive. Prevalence increased with age, particularly in women aged 35–40 years and over 40 years. No significant associations were found with education, number of children, family size, or history of blood transfusion and surgery, except for the occupation of the family head as a public officer. Of the total anti‐HEV positive women, 22.7% had anti‐HEV IgM, indicating recent or ongoing infection.ConclusionThe study concluded that the in‐house ELISA is a viable option for HEV screening in regions with limited resources due to its high accuracy and cost‐effectiveness. It is particularly suitable for large‐scale studies and public health interventions in areas where HEV is endemic and poses a significant risk to pregnant women.